

Patient Report

Specimen ID: Control ID:

Acct #:

Phone: (847) 222-9546

Rte: 31

DHA Laboratory 411 E. Business Center Dr Ste 107 Mount Prospect IL 60056

նվուկիցորմը իկնցրեցիկների հիմի հերևնկին կին հինակի

Patient Details

Specimen Details
Date collected:
Date received:
Date entered:
Date reported:

Physician Details

Ordering: D JOCKERS Referring: ID: 14430073 NPI: 1003051327

General Comments & Additional Information

Clinical Info: DO NOT BILL PATIENT. BIL

Clinical Info: L ACCOUNT 125
Alternate Control Number:

Total Volume: Not Provided

Alternate Patient ID: Not Provided

Fasting: Yes

Ordered Items

CBC With Differential/Platelet; Comp. Metabolic Panel (14); Urinalysis, Routine; Lipid Panel w/ Chol/HDL Ratio; Thyroid Panel With TSH; Iron and TIBC; Hemoglobin A1c; Thyroxine (T4) Free, Direct, S; Folate (Folic Acid), Serum; Testosterone, Serum; Plasma Zinc; Vitamin A, Serum; Reverse T3, Serum; Calcitriol(1,25 di-OH Vit D); Vitamin D, 25-Hydroxy; Fructosamine; Lipoprotein (a); C-Reactive Protein, Cardiac; Homocyst(e)ine; Uric Acid; LDH; GGT; Triiodothyronine (T3); Sedimentation Rate-Westergren; Thyroglobulin Antibody; Vitamin B12; Magnesium; Copper, Serum; Fibrinogen Activity; Insulin; Ferritin, Serum; Thyroid Peroxidase (TPO) Ab; Triiodothyronine (T3), Free; PTH, Intact; Venipuncture

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
CBC With Differential/Plate	let				
WBC	6.5		x10E3/uI	3.4 - 10.8	01
RBC	4.55		x10E6/uI	4.14 - 5.80	01
Hemoglobin	14.7		g/dL	13.0 - 17.7	01
Hematocrit	44.3		%	37.5 - 51.0	01
MCV	97		fL	79 - 97	01
MCH	32.3		pg	26.6 - 33.0	01
MCHC	33.2		g/dL	31.5 - 35.7	01
RDW	13.6		%	12.3 - 15.4	01
Platelets	297		x10E3/uI	150 - 450	01
Neutrophils	67		%	Not Estab.	01
Lymphs	25		%	Not Estab.	01
Monocytes	6		%	Not Estab.	01
Eos	2		%	Not Estab.	01
Basos	0		%	Not Estab.	01
Neutrophils (Absolute)	4.4		x10E3/uI	1.4 - 7.0	01
Lymphs (Absolute)	1.6		x10E3/uI	0.7 - 3.1	01
Monocytes (Absolute)	0.4		x10E3/uI	0.1 - 0.9	01
Eos (Absolute)	0.2		x10E3/uI	0.0 - 0.4	01
Baso (Absolute)	0.0		x10E3/uI	0.0 - 0.2	01
Immature Granulocytes	0		%	Not Estab.	01
Immature Grans (Abs)	0.0		x10E3/uI	0.0 - 0.1	01

Comp. Metabolic Panel (14)



TESTS	RESULT	FLAG	UNITS RI	EFERENCE INTERVAL	LAB
Glucose	116	High	mg/dL	65 - 99	01
BUN	19		mg/dL	8 - 27	01
Creatinine	1.05		mg/dL	0.76 - 1.27	01
eGFR If NonAfricn Am	70		mL/min/1.73	>59	
eGFR If Africn Am	81		mL/min/1.73	>59	
BUN/Creatinine Ratio	18			10 - 24	
Sodium	144		${\tt mmol/L}$	134 - 144	01
Potassium	4.8		${\tt mmol/L}$	3.5 - 5.2	01
Chloride	103		${\tt mmol/L}$	96 - 106	01
Carbon Dioxide, Total	28		${\tt mmol/L}$	20 - 29	01
Calcium	10.1		mg/dL	8.6 - 10.2	01
Protein, Total	7.2		g/dL	6.0 - 8.5	01
Albumin	5.2	High	g/dL	3.5 - 4.8	01
Globulin, Total	2.0		g/dL	1.5 - 4.5	
A/G Ratio	2.6	High		1.2 - 2.2	
Bilirubin, Total	0.6		mg/dL	0.0 - 1.2	01
Alkaline Phosphatase	56		IU/L	39 - 117	01
AST (SGOT)	20		IU/L	0 - 40	01
ALT (SGPT)	6		IU/L	0 - 44	01
Urinalysis, Routine					
Urinalysis Gross Exam					01
Specific Gravity	1.027			1.005 - 1.030	01
рН	5.0			5.0 - 7.5	01
Urine-Color	Yellow			Yellow	01
Appearance	Clear			Clear	01
WBC Esterase	Negative			Negative	01
Protein	Negative			Negative/Trace	01
Glucose	Negative			Negative	01
Ketones	Negative			Negative	01
Occult Blood	Negative			Negative	01
Bilirubin	Negative			Negative	01
Urobilinogen,Semi-Qn	0.2		mg/dL	0.2 - 1.0	01
Nitrite, Urine	Negative			Negative	01
Microscopic Examination					01
Microscopic not indicate	ed and not	performed			
Lipid Panel w/ Chol/HDL Ratio					
Cholesterol, Total	239	High	mg/dL	100 - 199	01
Triglycerides	44		mg/dL	0 - 149	01
HDL Cholesterol	85		mg/dL	>39	01
VLDL Cholesterol Cal	9		mg/dL	5 - 40	
LDL Cholesterol Calc	145	High	mg/dL	0 - 99	
Date Issued: 10/20/19 1606 FT	FINI	AI DEDORT			Page 2 of 5

Date Issued: 10/20/19 1606 ET FINAL REPORT Page 2 of 5



TESTS	RESULT	FLAG		EFERENCE INTERVAI	LAB	
T. Chol/HDL Ratio	2.8		ratio	0.0 - 5.0	01	
Please Note:	ote: T. Chol/HDL Ratio					
			1. CII	Men Women		
			1/2 Avg.R	isk 3.4 3.3		
			Avg.R			
			2X Avg.R 3X Avg.R	isk 9.6 7.1 isk 23.4 11.0		
			5			
Thyroid Panel With TSH			/ -			
TSH	1.640		uIU/mL	0.450 - 4.500	01	
Thyroxine (T4)	6.4		ug/dL	4.5 - 12.0	01	
T3 Uptake	27		%	24 - 39	01	
Free Thyroxine Index	1.7			1.2 - 4.9		
Iron and TIBC						
<pre>Iron Bind.Cap.(TIBC)</pre>	457	High	ug/dL	250 - 450		
UIBC	298		ug/dL	111 - 343	01	
Iron	159		ug/dL	38 - 169	01	
Iron Saturation	35		%	15 - 55		
Hemoglobin Alc						
Hemoglobin Alc	5.9	High	%	4.8 - 5.6	01	
Please Note:		-			01	
Prediabetes: 5.	7 - 6.4					
Diabetes: >6.4 Glycemic contro	l for adult	-a with	diahetes. /7	0		
Grycemic contro	I IOI addit	25 WICH	diabetes. </td <td>. 0</td> <td></td>	. 0		
Thyroxine (T4) Free, Direct,	S					
T4,Free(Direct)	1.27		ng/dL	0.82 - 1.77	01	
Folate (Folic Acid), Serum						
Folate (Folic Acid), Serum	>20.0		ng/mL	>3.0	01	
Note:			5,		01	
A serum folate concentra						
considered to represent	clinical de	eficienc	у.			
Testosterone, Serum	601		ng/dL	264 - 916	01	
Adult male reference int			a population	of	-	
healthy nonobese males (
Travison, et.al. JCEM 20	17,102;116.	1-11/3.	PMID: 283241	03.		
Plasma Zinc	115		ug/dL	56 - 134	02	
				on Limit = 5		
Vitamin A, Serum						
Vitamin A	69.9	High	ug/dL	22.0 - 69.5	02	
Reference intervals for					J <u>-</u>	



TESTS	RESULT	FLAG	UNITS I	REFERENCE INTERVAL	LAB			
studies. Individuals with vitamin A less than 20 ug/dL are considered vitamin A deficient and those with serum concentrations less than 10 ug/dL are considered severely deficient. This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.								
Reverse T3, Serum A	13.7		ng/dL	9.2 - 24.1	02			
Calcitriol(1,25 di-OH Vit D)	55.5		pg/mL	19.9 - 79.3	02			
Vitamin D, 25-Hydroxy 63.1 Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2). 1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press. 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30.								
Fructosamine 346 High umol/L 0 - 285 Published reference interval for apparently healthy subjects between age 20 and 60 is 205 - 285 umol/L and in a poorly controlled diabetic population is 228 - 563 umol/L with a mean of 396 umol/L.								
i: b t. i:	ndicate an i ut must be e o non-Caucas	ndepende: evaluated sian popu	nt risk fac with caut: lations due	<75.0 75.0 nmol/L may ctor for CHD, ion when applied to the Lp(a) across	02			
C-Reactive Protein, Cardiac	<0.15 Relative Ri	lsk for F	mg/L uture Card: Low Average High	0.00 - 3.00 iovascular Event <1.00 1.00 - 3.00 >3.00	01			
Homocyst(e)ine	13.0		umol/L	0.0 - 15.0	01			
Uric Acid Uric Acid Please Note:	3.9 Therapeut	cic targe	mg/dL t for gout	3.7 - 8.6 patients: <6.0	01 01			

Date Issued: 10/20/19 1606 ET FINAL REPORT Page 4 of 5



TESTS	RESULT	FLAG	UNITS RE	FERENCE INTERVAL	LAB
LDH	167		IU/L	121 - 224	01
GGT	15		IU/L	0 - 65	01
Triiodothyronine (T3)	96		ng/dL	71 - 180	01
Sedimentation Rate-Westergre	n 2		mm/hr	0 - 30	01
Thyroglobulin Antibody Thyroglobulin Antibody	<1.0 measured by	Beckman	IU/mL Coulter Meth	0.0 - 0.9 odology	01
Vitamin B12	1200		pg/mL	232 - 1245	01
Magnesium	2.3		mg/dL	1.6 - 2.3	01
Copper, Serum B	64	Low	ug/dL Detectio	72 - 166 n Limit = 5	02
Fibrinogen Activity	234		mg/dL	193 - 507	01
Insulin	5.8		uIU/mL	2.6 - 24.9	01
Ferritin, Serum	90		ng/mL	30 - 400	01
Thyroid Peroxidase (TPO) Ab	23		IU/mL	0 - 34	01
Triiodothyronine (T3), Free	3.1		pg/mL	2.0 - 4.4	01
PTH, Intact	42		pg/mL	15 - 65	01

Comments:

- A This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.
- ^B This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.